Pear Therapeutics (PEAR) Tops Q1 EPS by 7c

Go back to Pear Therapeutics (PEAR) Tops Q1 EPS by 7c

Pear Therapeutics Reports First Quarter 2022 Financial Results

May 16, 2022 4:02 PM EDT

108% quarter-over-quarter revenue growth to $2.7 million >9,200 total prescriptions in the first quarter for Pears three FDA-authorized products Expanded patient access with state payors in Michigan and Oklahoma CMS issued new HCPCS code Pear's first 12-month and 24-month real-world health economic data presented at ISPOR

BOSTON--(BUSINESS WIRE)-- Pear... More